Get the Stockscreener App
1.95
41.30%
0.57
After Hours:
1.97
0.02
+1.03%
Cyclerion Therapeutics Inc stock is traded at $1.95, with a volume of 71.26M.
It is up +41.30% in the last 24 hours and up +16.07% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$1.38
Open:
$2.17
24h Volume:
71.26M
Relative Volume:
46.86
Market Cap:
$7.42M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-0.9112
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
+65.25%
1M Performance:
+16.07%
6M Performance:
-41.96%
1Y Performance:
-37.90%
1-Day Range:
$1.86
$2.28
1-Week Range:
$1.1997
$2.28
52-Week Range:
$1.16
$6.25
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
1.95 | 5.25M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
Exciting Surge in Cyclerion: What’s Next? - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cyclerion, Medsteer form strategic anesthetic technology alliance - TipRanks
Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next - ts2.tech
Morning Market Movers: CYCN, AZI, AEVA, OS See Big Swings - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Cyclerion Expands Partnership With Medsteer; Plans Phase 2 Trial Of CYC-126 In 2H 2026; Stock Up - Nasdaq
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Cyclerion Therapeutics Inc. (CYCN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cyclerion Therapeutics (CYCN) Enhances Depression Treatment Prog - GuruFocus
Cyclerion partners with Medsteer to advance depression treatment platform - Investing.com India
Cyclerion Therapeutics stock soars after strategic Medsteer collaboration - Investing.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Cyclerion Therapeutics, Inc. Announces Progress Toward Initiating Phase 2 Proof-Of-Concept Study for CYC-126 in Treatment-Resistant Depression - marketscreener.com
Cyclerion partners with Medsteer to advance depression treatment platform By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ICICI Prudential AMC Ltd (542629) Quarterly Results Are OutMonthly Performance Summary & Superior Wealth Building - bollywoodhelpline.com
Cyclerion Therapeutics Inc Stock Analysis and ForecastDividend Stability Analysis & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ) - Defense World
Panjon Limited Flashes Buy Signal on Multi Timeframe ChartMoving Average Crossovers & High Return Wealth Building - bollywoodhelpline.com
Is Cyclerion Therapeutics Inc. stock a safe buy before earningsFibonacci Retracement Levels & Low Cost Trading Ideas - bollywoodhelpline.com
Cyclerion Therapeutics Relaunches with Neuropsychiatric Focus - MSN
Will Cyclerion Therapeutics Inc. stock reach all time highs in 2025Weekly Trend Summary & Reliable Entry Point Alerts - Улправда
Should I hold or sell Cyclerion Therapeutics Inc. stock in 20252025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
How Cyclerion Therapeutics Inc. stock benefits from strong dollarJuly 2025 Institutional & Daily Risk Controlled Trade Plans - Улправда
Rate Hike: Will Cyclerion Therapeutics Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Stock Portfolio Risk Management - Улправда
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 0.7% – Should You Sell? - Defense World
Cyclerion Therapeutics Earnings Notes - Trefis
Can Cyclerion Therapeutics Inc. stock sustain institutional interestTrade Performance Summary & Safe Swing Trade Setups - Newser
Does Cyclerion Therapeutics Inc. stock trade at a discount to peersWeekly Loss Report & Verified Momentum Watchlists - Newser
How currency fluctuations impact Cyclerion Therapeutics Inc. stockJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - Newser
Cyclerion Therapeutics (CYCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Cyclerion Therapeutics Inc. stock attractive for growth ETFsPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Cyclerion Therapeutics Announces Milestone Payment from Akebia - TradingView — Track All Markets
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Cyclerion Therapeutics, Inc. Announces Revision in Its Stock Evaluation Amid Financial Trends - Markets Mojo
How strong is Cyclerion Therapeutics Inc. stock balance sheetBond Market & Real-Time Stock Movement Alerts - newser.com
Will Cyclerion Therapeutics Inc. stock maintain growth story2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Smart tools for monitoring Cyclerion Therapeutics Inc.’s price actionStop Loss & Fast Gain Stock Trading Tips - newser.com
What institutional flow reveals about Cyclerion Therapeutics Inc.Quarterly Profit Report & AI Forecasted Entry and Exit Points - newser.com
Combining machine learning predictions for Cyclerion Therapeutics Inc.Weekly Stock Summary & Daily Volume Surge Signals - newser.com
Tick level data insight on Cyclerion Therapeutics Inc. volatilityRecession Risk & Trade Opportunity Analysis - newser.com
Why Cyclerion Therapeutics Inc. stock is recommended by analystsEarnings Performance Report & Fast Entry Momentum Trade Alerts - newser.com
What MACD and RSI say about Cyclerion Therapeutics Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Is Cyclerion Therapeutics Inc. stock reversal real or fakeJuly 2025 Outlook & Real-Time Stock Price Movement Reports - newser.com
Live market analysis of Cyclerion Therapeutics Inc.Weekly Investment Recap & Expert Curated Trade Ideas - newser.com
Is Cyclerion Therapeutics Inc. stock a top pick in earnings seasonWeekly Stock Report & Short-Term Trading Opportunity Alerts - Fundação Cultural do Pará
Is Cyclerion Therapeutics Inc a good long term investmentLong-Term Growth Stocks & You’ve Never Seen Stock Picks Like These - earlytimes.in
Comparing Cyclerion Therapeutics Inc. in custom built stock radarsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):